Cue Biopharma Executive Compensation Details Released
Ticker: CUE · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1645460
| Field | Detail |
|---|---|
| Company | Cue Biopharma, Inc. (CUE) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Cue Biopharma dropped exec comp details for 2024. Equity awards are the focus.
AI Summary
Cue Biopharma, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to both "PEO" (Principal Executive Officer) and "Non-PEO" (Non-Principal Executive Officer) members, with specific data points for the fiscal years 2022, 2023, and 2024. This includes year-end fair values of outstanding and unvested equity awards.
Why It Matters
This filing provides transparency into how Cue Biopharma compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: low — This is a routine filing providing information on executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for executive compensation data)
- 2023 — Fiscal Year End (Previous reporting period for executive compensation data)
- 2022 — Fiscal Year End (Earlier reporting period for executive compensation data)
Key Players & Entities
- Cue Biopharma, Inc. (company) — Filer of the DEF 14A
- Imagen Biopharma, Inc. (company) — Former company name
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit shareholder votes on important matters, such as the election of directors and executive compensation, and provides detailed information about these proposals.
What specific types of equity awards are detailed in this filing for Cue Biopharma?
The filing details equity awards granted, including year-end fair values of outstanding and unvested equity awards for both PEO (Principal Executive Officer) and Non-PEO members.
For which fiscal years does this filing provide executive compensation data?
This filing provides executive compensation data for the fiscal years ending December 31, 2024, 2023, and 2022.
What was Cue Biopharma's former company name?
Cue Biopharma, Inc. was formerly known as Imagen Biopharma, Inc., with a name change occurring on June 17, 2015.
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc. is headquartered at 40 Guest Street, Boston, MA 02135.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Cue Biopharma, Inc. (CUE).